Subscribe

Humanwell Healthcare (Group) Co.,Ltd. (600079.SS)

CNY17.70 +0.11 (+0.63%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address No.666 Gaoxin Road 430075
Wuhan, CN
CEO Wentao Du
Website humanwell.com.cn
IPO 1997-06-06
ISIN CNE000000QW6

Explore sections of this company profile

Description

Humanwell Healthcare (Group) Co.,Ltd. operates internationally, delivering a wide spectrum of healthcare solutions across regions including the Asia Pacific, North America, and Africa. The company's diverse product range features pharmaceuticals for pain management, such as anesthetics and analgesics, alongside a significant focus on women's health, providing items for reproductive planning, emergency contraception, and general wellness. They also produce central nervous system (CNS) medications addressing conditions like bronchitis, migraines, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, brain injuries, and peripheral vascular disorders. Furthermore, their offerings extend to traditional herbal remedies for common ailments such as colds and flu, rheumatoid arthritis, dermatological concerns, hepatitis, urinary tract infections, and memory impairment. Humanwell also supplies anti-infective agents, a variety of over-the-counter (OTC) drugs for digestive complaints, cold and flu relief, anti-inflammatory purposes, infections, and nutritional supplements. Complementing these, they offer specific treatments aimed at cardiovascular, gastrointestinal, and reproductive system diseases. Established in Wuhan, China, in 1993, the enterprise was initially known as Wuhan Humanwell Healthcare (Group) Co., Ltd. before adopting its current name, Humanwell Healthcare (Group) Co.,Ltd., in March 2013.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY17.70 +0.11 (+0.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.41
Float Shares
1.19B
Free Float %
72.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.69% -1.96% -7.31% -11.71% -9.47% -3.37% -21.10% -32.85% -38.10% +8.36% +894.32%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
17.70
DCF (Unlevered) 21.96 +24.1%
DCF (Levered) 4.81 -72.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 80% Bullish
Rating 2024-11 Change
Strong Buy 2 0
Buy 6 0
Hold 2 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.82
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -5.8% Q1'26: -0.6% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +39.0% ★ Q1'26: +9.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +4.9% ★ Q1'26: +3.1% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +13.9% ★ Q1'26: +15.8% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +10.7% ★ Q1'26: +12.0% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.4% Q1'26: -0.3% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    1.96× Q1'26: 2.38× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.49) × ERP
WACC = 77% × Ke + 23% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 21.96 Current price: 17.70
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
2 Rev. Ana.
1 EPS Ana.
Revenue
10.05B
est: 9.33B (+7.7%)
12.33B
est: 12.72B (-3.1%)
15.45B
est: 14.65B (+5.4%)
18.63B
est: 18.12B (+2.8%)
21.81B
est: 20.74B (+5.1%)
20.68B
est: 21.26B (-2.7%)
20.55B
est: 20.46B (+0.4%)
22.34B
est: 22.10B (+1.1%)
24.52B
est: 24.98B (-1.8%)
25.44B
est: 26.00B (-2.2%)
23.96B
est: 24.92B (-3.8%)
27.07B
26.50B – 27.63B
+8.6% YoY
29.48B
28.57B – 30.38B
+8.9% YoY
EBITDA
1.34B
est: 1.45B (-8.0%)
1.76B
est: 1.98B (-11.1%)
2.08B
est: 2.28B (-8.9%)
2.35B
est: 2.82B (-16.9%)
3.07B
est: 3.23B (-4.9%)
3.34B
est: 3.31B (+0.7%)
3.02B
est: 3.19B (-5.3%)
3.37B
est: 3.44B (-2.1%)
4.11B
est: 3.89B (+5.5%)
3.88B
est: 5.62B (-31.0%)
4.36B
est: 5.38B (-19.0%)
5.85B
5.72B – 5.97B
+8.6% YoY
6.37B
6.17B – 6.56B
+8.9% YoY
EBIT
1.08B
est: 1.15B (-5.7%)
1.34B
est: 1.57B (-14.5%)
1.56B
est: 1.80B (-13.3%)
1.80B
est: 2.23B (-19.4%)
2.49B
est: 2.55B (-2.3%)
2.66B
est: 2.62B (+1.4%)
2.36B
est: 2.52B (-6.3%)
2.65B
est: 2.72B (-2.7%)
3.32B
est: 3.08B (+7.9%)
3.01B
est: 4.22B (-28.5%)
3.33B
est: 4.04B (-17.6%)
4.39B
4.30B – 4.48B
+8.6% YoY
4.78B
4.63B – 4.93B
+8.9% YoY
Net Income
653.82M
est: 796.19M (-17.9%)
832.40M
est: 1.14B (-26.8%)
2.07B
est: 2.57B (-19.4%)
-2.36B
est: 989.27M (-338.3%)
842.54M
est: 1.05B (-20.1%)
1.01B
est: 1.12B (-10.1%)
1.32B
est: 1.51B (-12.7%)
2.48B
est: 2.51B (-1.2%)
2.13B
est: 2.18B (-1.9%)
1.33B
est: 2.22B (-40.1%)
1.86B
est: 2.10B (-11.8%)
2.38B
2.12B – 2.63B
+12.9% YoY
2.67B
2.58B – 2.76B
+12.3% YoY
SGA
2.43B
est: 2.38B (+1.9%)
3.03B
est: 3.25B (-6.8%)
3.69B
est: 3.74B (-1.2%)
4.89B
est: 4.62B (+5.8%)
5.34B
est: 5.29B (+1.0%)
5.08B
est: 5.42B (-6.3%)
5.33B
est: 5.22B (+2.1%)
5.83B
est: 5.64B (+3.4%)
6.17B
est: 6.37B (-3.2%)
6.56B
est: 6.17B (+6.4%)
3.74B
est: 5.91B (-36.8%)
6.42B
6.28B – 6.55B
+8.6% YoY
6.99B
6.77B – 7.20B
+8.9% YoY
EPS
0.52
est: 0.49 (+5.9%)
0.65
est: 0.70 (-7.3%)
1.53
est: 1.58 (-3.3%)
-1.81
est: 0.61 (-396.7%)
0.62
est: 0.65 (-4.0%)
0.73
est: 0.69 (+5.8%)
0.83
est: 0.93 (-10.8%)
1.54
est: 1.55 (-0.6%)
1.32
est: 1.37 (-3.6%)
0.82
est: 1.33 (-38.3%)
1.14
est: 1.31 (-13.0%)
1.46
1.30 – 1.62
+11.5% YoY
1.64
1.58 – 1.70
+12.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-28 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-27 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-26 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-25 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-22 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-21 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-20 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-19 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-18 B+ 3/5 3/5 4/5 4/5 2/5 2/5 3/5
2026-05-15 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-14 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-13 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-12 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-11 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-08 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-07 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-05-06 A- 4/5 3/5 4/5 4/5 2/5 3/5 4/5
2026-04-30 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-29 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-28 B+ 3/5 3/5 3/5 4/5 1/5 3/5 4/5
2026-04-27 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-24 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-23 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-22 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-21 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 B+ 3/5 3/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.12B
OE per share TTM
1.30
Owner's Yield
7.44%
Maintenance CapEx ratio
18.01%
Maint CapEx / Avg PPE
37.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 5 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 HSBC MSCI China A UCITS ETF HMCT.L 0.09% 126.0K 0.30%
2 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.01% 39.4K 0.44%
3 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 147.6K 0.39%
4 Dimensional - Emerging Markets Value ETF DFEV 0.00% 23.9K 0.46%
5 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 45.2K 0.29%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
188.5K
Shares Outstanding
1.63B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chenggang Zheng Deputy General Manager — male
Hongjie Zhang Vice President — male
Hua Qin He Accounting Supervisor — —
Jun Li Deputy General Manager — male
Lie Li Vice President — female
Nanhong Liu Deputy GM & Board Secretary — male
Qiang Yin Deputy General Manager — male
Qun Yu Vice President — male
Wentao Du GM & Financial Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic